Navigation Links
Cambrex Appoints Steven M. Klosk as President and CEO
Date:5/15/2008

EAST RUTHERFORD, N.J., May 15 /PRNewswire-FirstCall/ -- Cambrex (NYSE: CBM), a leading life sciences company, announced today that the Board of Directors appointed Steven M. Klosk, President and Chief Executive Officer and a member of the Cambrex Corporation Board of Directors effective May 14, 2008. James A. Mack, President and Chief Executive Officer since 1995 and Chairman since 1999, has announced he will step down. The Company will separate the positions of Board Chairman and CEO and John R. Miller, currently lead director, will assume the position of Non-Executive Chairman of the Board. Mr. Mack will remain a Board member and advisor until his retirement on June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

Mr. Klosk, 51, joined Cambrex in October 1992 as Vice President-Administration. He was appointed Executive Vice President, Administration in October 1996, and was promoted to the position of Executive Vice President and Chief Operating Officer for Cambrex Pharma and BioPharmaceutical Business Unit in October 2003. In January 2005 Mr. Klosk assumed direct responsibility for the BioPharmaceutical Business Unit as Chief Operating Officer. In January 2007 he was appointed Executive Vice President and Chief Operating Officer for the Corporation. He holds a Bachelor of Science degree from Cornell University and a J. D. degree from New York Law School.

"I have enjoyed my many years with Cambrex and now is the right time to turn the Company over to new leadership. I am confident that with his many years with Cambrex, Steve will ably continue the pattern of growth that is so much a part of the Company," commented Mr. Mack.

"I am excited about the opportunity to lead the Cambrex team as we focus on our growth initiatives in proprietary products and polymeric drug delivery, highly potent compounds, controlled substances and our growing pipeline of new custom development products. In addition, we are well positioned to leverage our recently completed facility near Milan, Italy to support our leading position in generic active pharmaceutical ingredients," said Mr. Klosk. "I am extremely grateful to Jim for his many years of outstanding service to Cambrex and for his personal mentorship."

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients ("APIs"), advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit http://www.cambrex.com.


'/>"/>
SOURCE Cambrex
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):